Miscellaneous Neurodegenerative Disorders

Transdermal Nicotine May Benefit Cognitive Impairment

For nonsmokers with amnestic mild cognitive impairment (MCI), use of a transdermal nicotine patch for six months is associated with improved cognitive test performance, but not clinical global impression of change.

Nuedexta approved for pseudobulbar affect

Avanir Pharmaceuticals announced that the FDA has approved Nuedexta (dextromethorphan hydrobromide and quinidine sulfate capsules) for the treatment of pseudobulbar affect (PBA).